Group items tagged

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

The Department of Health and Social Care (DHSC) has decided to enforce an 'indefinite' ban on the sale and supply of puberty blockers via private prescriptions for the treatment of gender incongruence and/or gender dysphoria in under-18s in the UK. This decision follows official advice from the Commission on Human Medicines (CHM), which found an "unacceptable safety risk" in the continued prescription of puberty blockers to children. The CHM, tasked by the health secretary and Northern Ireland Minister for Health to evaluate the safety of gonadotropin-releasing hormone (GnRH) agonists for puberty suppression, issued eight recommendations. It advised that a statutory indefinite ban be placed on the use of puberty blockers until its three recommended structures are in place to support safe UK prescribing.